A Single Center, Double-blind, Randomized, Placebo-controlled, Parallel, Single and Repeat, Dose-ascending Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK2269557 Administered Via the ELLIPTA™ Dry Powder Inhaler to Healthy Japanese Subjects
Phase of Trial: Phase I
Latest Information Update: 20 Jan 2017
At a glance
- Drugs GSK 2269557 (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions; Pharmacokinetics
- Sponsors GlaxoSmithKline
- 16 Jan 2017 Status changed from active, no longer recruiting to completed.
- 16 Dec 2016 Status changed from recruiting to active, no longer recruiting.
- 28 Nov 2016 New trial record